Product Center
The first domestic quadrivalent influenza virus subunit vaccine achieves a new breakthrough in providing comprehensive protection for all age groups
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-10-30
- Views:
(Summary description)This flu season has arrived early and intensely. Surveillance data from multiple countries and regions in East Asia show that influenza virus activity is significantly higher than in the same period of previous years. Flu activity is rising in southern provinces of China. According to the latest flu surveillance data released by the Chinese Center for Disease Control and Prevention, the percentage of influenza-like cases reported by sentinel hospitals in southern provinces reached 3.8%.
The first domestic quadrivalent influenza virus subunit vaccine achieves a new breakthrough in providing comprehensive protection for all age groups
(Summary description)This flu season has arrived early and intensely. Surveillance data from multiple countries and regions in East Asia show that influenza virus activity is significantly higher than in the same period of previous years. Flu activity is rising in southern provinces of China. According to the latest flu surveillance data released by the Chinese Center for Disease Control and Prevention, the percentage of influenza-like cases reported by sentinel hospitals in southern provinces reached 3.8%.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-10-30 08:55
- Views:
This flu season has arrived early and intensely. Surveillance data from multiple countries and regions in East Asia show that influenza virus activity is significantly higher than in the same period of previous years. Flu activity is rising in southern provinces of China. According to the latest flu surveillance data released by the Chinese Center for Disease Control and Prevention, the percentage of influenza-like cases reported by sentinel hospitals in southern provinces reached 3.8%.
In September 2025, China's first quadrivalent influenza virus subunit vaccine suitable for the entire population aged 6 months and above— HRK-X®—officially received approval from the National Medical Products Administration to expand its age range. This marks the final piece of the "all-age protection" puzzle for quadrivalent influenza virus subunit vaccines, particularly as infants and young children require a high-quality influenza vaccine with fewer adverse reactions and superior protection. The approval of HRK-X®'s age expansion fills the gap in China's high-end influenza vaccine market for infants and young children.
Clinical data confirms that the tetravalent influenza virus subunit vaccine demonstrates superior safety. According to findings published in the international vaccine journal《Vaccine》, this tetravalent influenza virus subunit vaccine induces significantly lower fever reactions in children aged 3-8 years compared to the control group, accounting for only 46% of the control group's rate. The incidence of local adverse reactions in infants and young children after vaccination is 54% of that seen with the control group's split vaccine. Additionally, the vaccine employs isotonic technology and five-sided minimally invasive needles, effectively reducing injection pain by 33% and bleeding rates by 21%, greatly enhancing the vaccination experience and compliance for special populations such as infants, young children, and the elderly.
Meanwhile, the《Chinese Technical Guidelines for Influenza Vaccination (2023-2024)》clearly states that from the perspective of vaccine manufacturing processes, subunit vaccines remove internal viral proteins and retain only the high-purity HA and NA antigen components, offering superior safety compared to split vaccines.
Currently, 26 provinces across the country have completed the age extension approval process. As the peak flu season in autumn and winter approaches, the quadrivalent influenza virus subunit vaccine is being rapidly rolled out for expanded age groups nationwide. Cities such as Shenyang, Jinan, Shanghai, Wuhan, Kunming, and Fuzhou have already administered the first doses of this vaccine for the expanded age group.
Zhang Shanying, Honorary Director of the Popular Science Branch of the Fujian Medical Association, pointed out, "The newly approved quadrivalent influenza virus subunit vaccine for expanded age groups marks a new milestone in the development, production, and application of influenza vaccines in China, particularly filling the gap in high-level protection for young children."
The expansion of the age range directly reflects in the booming market data, with the company now clearing its inventory and fully releasing products to the market. The primary drivers of this growth include the incremental market (infant and young child populations) brought by the age range expansion, as well as the dual pursuit of vaccine safety and efficacy amid the pandemic outbreak. Market share surge: Within the entire influenza vaccine market, the share of the quadrivalent influenza virus subunit vaccine has significantly increased, with some regions already experiencing a shortage of single doses.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
